



2013

Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells [poster abstract]

Kyle K. Payne

Virginia Commonwealth University, paynekk2@vcu.edu

Christine K. Zoon

Virginia Commonwealth University, CZoon@mcvh-vcu.edu

Wen Wan

Virginia Commonwealth University, wwan@vcu.edu

See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/massey_pubs

 Part of the [Medicine and Health Sciences Commons](#)

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from

http://scholarscompass.vcu.edu/massey_pubs/1

This Article is brought to you for free and open access by the Massey Cancer Center at VCU Scholars Compass. It has been accepted for inclusion in Massey Cancer Center Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Authors

Kyle K. Payne, Christine K. Zoon, Wen Wan, Khin Marlar, Rebecca C. Keim, Mehrab Nasirir Kenari, Latif Kazim, Harry D. Bear, and Masoud H. Manjili

POSTER PRESENTATION

Open Access

Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells

Kyle K Payne^{1*}, Christine K Zoon¹, Wen Wan¹, Khin Marlar², Rebecca C Keim¹, Mehrab Nasiri Kenari², Latif Kazim², Harry D Bear¹, Masoud H Manjili¹

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Barriers limiting the efficacy of adoptive cellular therapy (ACT) for breast cancer patients include immune suppression mediated by myeloid-derived suppressor cells (MDSC) and a low frequency of tumor-reactive memory T cells (Tm). Recently, we developed an ex vivo protocol to reprogram tumor-reactive murine splenocytes; these cells were found to be resistant to MDSC suppression and protected FVBN202 mice from tumor challenge. Here, we evaluated the clinical applicability of reprogramming tumor-sensitized PBMCs isolated from patients with early stage breast cancer by treatment with bryostatin 1 and ionomycin (B/I) combined with IL-2, IL-7 and IL-15. Our data demonstrate that reprogrammed cells are enriched with Tm cells (n=5; p=0.006), as well as activated CD56⁺ (n=6; p=0.003) and CD161⁺ (n=4; p=0.02) NKT cells, and demonstrate expansion in total cell numbers (n=16; p=0.003) compared to baseline cells. Reprogrammed PBMCs displayed enhanced HER-2/neu-specific IFN- γ producing immune responses (n=6; p=0.04); non-reprogrammed control PBMC IFN- γ production was not significant (n=6; p=0.4). Furthermore, high-throughput sequencing analysis of the T cell receptor (TcR) V β in one patient demonstrated clonal expansion of specific TcR VJ recombination events resulting from cellular reprogramming, suggestive of an

enriched frequency of specific tumor antigen-primed T cell clones. Interestingly, reprogrammed T cells were resistant to autologous CD33⁺ CD11b⁺ HLA-DR^{lo/-} MDSCs, as determined by further enhanced HER-2/neu-specific IFN- γ secretion in the presence of MDSCs (n=6; p=0.03). Activated CD161⁺ NKT cells comprising 3% or greater of total reprogrammed cells rendered T cells resistant to MDSCs (n=3; p=0.02). Upregulation of NKG2D expression on CD161⁺ (n=5; p=0.0006) and CD56⁺ (n=5; p=0.04) NKT cells resulted from cellular reprogramming. Therefore, NKG2D signaling was blocked using anti-NKG2D blocking antibody in our co-culture system, resulting in the abrogation of resistance to MDSCs as determined by blunted IFN- γ secretion (n=3; p=0.04). Finally, the phenotype of MDSCs after co-culture with reprogrammed PBMC was examined; we observed down-regulation of CD11b expression (n=3; p=0.02) concomitant with HLA-DR upregulation on MDSCs (n=3; p=0.001); suggestive of induced maturation of MDSCs into Dendritic Cells (DC). The results of our study offer the following strategies to improve ACT of breast cancer: i) inclusion of activated NKT cells in ACT to overcome MDSC suppression by inducing MDSC maturation into DCs, and ii) PBMC reprogramming to enrich the frequency of tumor-reactive Tm cells.

¹Virginia Commonwealth University - Massey Cancer Center, Richmond, VA, USA

Full list of author information is available at the end of the article

Authors' details

¹Virginia Commonwealth University - Massey Cancer Center, Richmond, VA, USA. ²Roswell Park Cancer Institute, Buffalo, NY, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P170

Cite this article as: Payne *et al.*: Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. *Journal for ImmunoTherapy of Cancer* 2013 1(Suppl 1):P170.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

